Trastuzumab , the humanized human epidermal growth factor receptor 2 ( HER2 ) monoclonal antibody , and lapatinib , an epidermal growth factor receptor / HER2 tyrosine kinase inhibitor , are both established treatments for HER2 -overexpressing breast cancers .